This will take effect February 3, 2014
Overview and Clinical Utility:
PathGroup has increased regional coverage within our SmartGenomics™ solid tumor 35 gene next generation sequencing (NGS) panel from 112 to 140 amplicons in conjunction with a move of the test from the Ion PGM™ platform to the Illumina® MiSeq platform. Additionally, PathGroup has changed array comparative genomic hybridization (aCGH) platforms from the CombiMatrix DNArray™ Tumor Profile BAC array to the Illumina 850k CNV SNP array.
Click Here to read more.